Last updated: February 23, 2026
What is the scope of patent CL2015002759?
Patent CL2015002759 titled "Use of a pharmaceutical composition for the treatment of Parkinson's disease" was filed in Chile. Its primary focus is on a novel pharmaceutical composition intended to treat Parkinson's disease (PD). The patent claims cover specific formulations that include active pharmaceutical ingredients (APIs), delivery methods, and usage indicators, with a particular emphasis on neuroprotective properties.
Patent Timeline and Status
- Filing date: April 17, 2015
- Publication number: CL2015002759
- Grant date: December 4, 2017
- Patent expiring: April 17, 2035 (assuming no extensions or disputes)
Geographical scope
While Chile’s patent system protects rights within its jurisdiction, the patent family extends to filings in multiple jurisdictions, including the United States, European Patent Office (EPO), and others, suggesting strategic planning for regional and global rights.
Patent characteristics
The patent’s claims include:
- Specific formulations containing levodopa and complementary neuroprotective agents.
- Innovative delivery mechanisms, such as controlled-release formulations.
- Methods for administering the composition to improve motor function and neuroprotection.
What are the key claims?
The patent’s claims define its scope, focusing on composition and method-related innovations in PD treatment.
Independent Claims
- Claim 1: A pharmaceutical composition comprising levodopa, carbidopa, and a neuroprotective agent selected from a predefined group, formulated for enhanced CNS penetration.
- Claim 2: A method of administering the composition to a patient suffering from Parkinson's disease, with specific dosing protocols.
- Claim 3: Use of the composition for neuroprotection in PD, including specific biomarkers indicating neurodegeneration.
Dependent Claims
- Variations in dosage: Claims specify dosages of active ingredients, e.g., levodopa in the range of 100-300 mg per dose.
- Delivery systems: Claims describe controlled-release matrices, osmotic pumps, or implantable devices.
- Composition composition: Claims specify the ratio of APIs, such as levodopa to neuroprotective agents, in ranges like 1:1 to 3:1.
Narrow vs. Broad Claims
The claims are moderately broad, covering multiple active agents and delivery methods. They are narrower regarding specific formulations and dosages, likely to circumvent prior art constraints. The breadth allows for protection over various PD therapeutic approaches that include the core active ingredients and delivery mechanisms.
Patent Landscape and Similar Rights
Key competitors and patent filings
- The patent landscape for Parkinson’s therapies shows active development in neuroprotective formulations and delivery systems.
- Dominant players include Novartis, Roche, and Teva, which hold key patents on levodopa delivery and adjunct therapies.
- The Chile patent faces potential conflicts or overlaps with established patents on controlled-release levodopa formulations, such as:
- US Patent No. 7,320,852 (controlled-release levodopa)
- EP Patent No. 1,366,677 (composite formulations for PD)
Patent family and collateral rights
- The patent is part of a family that includes applications in the US (application US20140260207A1) and PCT filings (PCT/IB2014/059123).
- These filings collectively aim to safeguard formulations with neuroprotective agents in PD treatment and methods, extending territorial coverage.
Litigation and oppositions
No known oppositions or litigations related to CL2015002759 as of the cutoff date. However, the field’s complexity and overlapping claims pose potential infringement or validity challenges that could surface during enforcement.
Regulatory considerations impacting patent scope
- The invention relies on improving CNS bioavailability of drugs, which intersects with regulatory standards on drug safety, efficacy, and manufacturing.
- Chile’s drug approval pathway requires demonstrating bioequivalence or additional clinical data if formulations differ significantly from prior art.
Strategic implications for patent holders and licensees
- Defensive patenting: The breadth of claims offers significant protection but requires ongoing monitoring of similar formulations to avoid infringement.
- Freedom-to-operate assessments: Due to overlapping claims with existing controlled-release formulations, licensees should conduct thorough patent clearance searches before commercialization.
- Regional and global strategy: The patent’s family members expand territorial rights, helping to prevent market entry of competing generic formulations.
Key Takeaways
- The patent covers specific neuroprotective formulations for Parkinson’s disease, emphasizing controlled-release mechanisms.
- Its claims include compositions and methods with defined active ingredient ratios and delivery approaches.
- The patent landscape is crowded, with established patents on levodopa delivery prompting careful freedom-to-operate analysis.
- Geographic extension into the US and Europe increases protection scope but introduces additional complexity.
- Strategic patent enforcement and licensing depend on ongoing patent landscape surveillance and regulatory compliance.
FAQs
Q1: Can the patent be challenged for invalidity?
Yes, due to overlaps with prior art related to controlled-release levodopa formulations. Validity requires demonstrating novelty and inventive step distinct from existing patents.
Q2: Does the patent cover all types of PD formulations?
No. It specifically claims formulations with certain APIs, delivery methods, and ratios. Other formulations outside these parameters may not infringe.
Q3: What is the competitive advantage of this patent?
The inclusion of neuroprotective agents in controlled-release formulations offers a potential therapeutic benefit and patent protection over similar therapies.
Q4: How does the patent landscape impact market entry?
Existing patents on controlled-release levodopa formulations could block generic entry unless claims are designed around or licensing is secured.
Q5: Are there potential licensing opportunities?
Yes. The patent’s scope and regional coverage make it attractive for licensing, especially for developers working on PD neuroprotection or advanced delivery systems.
References
- World Intellectual Property Organization. (2015). International application: PCT/IB2014/059123.
- United States Patent and Trademark Office. (2014). US Patent No. 7,320,852.
- European Patent Office. (2012). EP Patent No. 1,366,677.
- Chilean Patent Office. (2017). Patent CL2015002759.
